The global home infusion therapy market size was valued at USD 33.5 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 8.0% from 2023 to 2030. Home infusion therapy refers to the process in which patients receive treatment at home through the administration of drugs or biologicals through catheters and needles. Receiving treatment at home as opposed to hospitals or healthcare facilities is a cost-effective and more convenient option for patients, further driving the need for home infusion therapy.
The Covid-19 pandemic had a positive impact on the home infusion market as the technique of home infusion was the need of the hour as healthcare settings were burdened with increasing covid patients. The regional and country-wide lockdowns had significantly affected operations and supply chains, but the market increased considerably in 2020. According to Medtech Dive, in October 2020, Baxter announced third-quarter sales of USD 2.97 billion, which is a 4% increase, due to the growing demand for its COVID-related medical products. Additionally, Baxter announced operational sales growth of 6% (3.2 billion) in Q3 2021 as compared to 3.0 billion in Q3 2020, reflecting the steady impact of pandemic recovery.
The COVID-19 pandemic led to a spike in the hospitalization of several people and often many were to be placed on ventilators. This occupied space in hospitals as the infected patients are to be placed where they will not contaminate patients and the healthcare professionals affecting them. Due to the increasing need for space and beds in hospitals, companies are focusing to transition patients from the hospital to in-home, creating demand for home infusion therapy. The key factors fueling the growth of the market include the increasing geriatric population with decreased mobility profile, rising preference for home care, and rapid technological advancements. Several conditions such as immune deficiencies, cancer, and congestive heart failure require infusion therapy as these conditions cannot be treated with oral medication. Since these patients require long-term treatment, home infusion therapy is considered a more cost-effective alternative to receiving treatment in hospitals.
Pandemic Impact |
Post COVID Outlook |
During the pandemic, emergency room visits were down by half or more, and admissions that are not related to COVID-19 also followed a similar or even more accelerated decline. |
Covid-19 uncovered the importance and effectiveness of in-house treatment & home infusion for diseases like cancer, diabetes, and cardiology |
The pandemic has resulted in a lower rate of emergency room utilization & hospitalizations, which led to demand for in-home medicine delivery settings |
The Cancer Care at Home program has made an addition of 12 chemotherapeutics, which formerly were not often provided through home infusion. Out of 670 patients enrolled in the program, 301 have been referred for home infusion, which is a 46% increase in the number of patients previously receiving in-house cancer treatment |
Smiths Medical stated that demand for infusion pumps increased substantially. The company’s revenue from infusion systems was up by 4%, driven by COVID-19 related demand |
In April 2020, FDA relaxed rules for infusion pumps & their accessories and stated that it will not object to companies making certain modifications to already cleared infusion pumps, which has a positive impact on the overall market |
In February 2020, the Cancer Care at Home program was launched by the Penn Center for Cancer Care Innovation at the University of Pennsylvania’s Abramson Cancer Center. It aimed to broaden the delivery of oncology treatments to patients in the home setting. From mid-March to late April, the company reported a 700% increase in the number of patients participating in the program. This highlights the bright future that lies ahead for the home infusion market in the years to come.
The infusion pumps segment accounted for the largest revenue share of over 51.0% in 2022 as these pumps are widely preferred for the delivery of nutrients and medications. On the basis of product, the market for home infusion therapy is segmented into infusion pumps, ambulatory infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The availability of a variety of products such as enteral, syringe, multichannel, and peristaltic pumps further contributes to the segment growth. The rising demand for syringes and ambulatory pumps owing to the increasing preference for home healthcare is also anticipated to contribute to the segment growth.
Nowadays, smart pumps are widely used as these pumps contain advanced features such as barcode technology, which helps in the verification of a patient’s identity and prevents drug administration errors. Needleless connectors are anticipated to register the highest CAGR over the forecast period. These connectors offer improved safety, enable smooth surgeries, and help adhere to good clinical practice (GCP), which contributes to the growth of the segment.
The anti-infective segment dominated the market for home infusion therapy in 2022 with a revenue share of over 26.9%. On the basis of application, the market has been segmented into anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, and specialty pharmaceuticals. This is attributed to the considerable number of procedures performed for the administration of antifungal and antibiotic drugs. It also helps reduce exposure to patients with other hospital-acquired infections (HAIs).
Chemotherapy is estimated to be the fastest-growing segment over the forecast period. With the growing incidences of cancer, the demand for pressure pumps is expected to increase in the coming years. Pumps used for chemotherapy at home are compact, continuous pressure pumps that do not require a battery and can hence be used for a longer period of time. With the help of these pumps, chemotherapy drugs can be administered at the appropriate infusion speed and in the right amounts.
North America dominated the market in 2022 with a revenue share of over 56.5% and this trend is expected to continue throughout the forecast period. This can be attributed to the increasing R&D in the region and the rising adoption of new technology in infusion pumps. The increasing need for long-term therapy for patients with certain conditions is driving the regional market. Development of alternate healthcare settings and home infusion services and shifting preference from acute care to home care settings due to the low cost and enhanced patient mobility would boost the growth of this market in the coming years.
The Asia Pacific market is expected to register the fastest CAGR of 9.9% over the forecast period. This is attributed to rising patient awareness regarding the benefits of home infusion therapy over in-hospital procedures and the growing prevalence of diabetes in the region. The growing geriatric population and the rise in chronic diseases in the region are expected to further fuel the market growth. According to the Times of India, around 75 million people over the age of 60 years suffer from some chronic disease in India, which might increase the adoption of home care services in the country.
The global market has been characterized by high competition. One of the key factors driving competitiveness among market players is the rapid adoption of advanced healthcare technology for improved healthcare services. Moreover, to retain market share and diversify their product portfolio, major players often adopt strategies such as mergers, acquisitions, and new product launches.
In December 2021, Baxter International completed the acquisition of Hillrom. This acquisition will help the company in broadening its geographic footprint and integrating medical device technology that will enhance patient care, lower costs, and increase workflow efficiency. In May 2021, Smiths Medical and Ivenix, Inc. announced a partnership agreement to offer a comprehensive suite of infusion management solutions in the U.S. market. This partnership is expected to evolve infusion management to improve patient safety.
In March 2021, Terumo and Glooko, a remote patient monitoring software and mobile apps company, announced technological integration to deliver new diabetes data solutions together globally. The partnership will allow the integration of data from Terumo's diabetes care devices into Glooko'sdiasend diabetes data management platform. In May 2020, Baxter International announced that the company had received CE marking and marketing approval from the Australian Therapeutic Goods Administration for Evo IQ Syringe Infusion System. Some prominent players in the global home infusion therapy market include:
CVS/Coram
Option Care Health
CareFusion Corporation
BriovaRx/Diplomat (UnitedHealth Optum)
PharMerica
Fresenius Kabi
ICU Medical, Inc.
B. Braun Melsungen AG
Baxter
BD
Caesarea Medical Electronics
Smiths Medical
Terumo Corporation
JMS Co. Ltd.
In June 2023, Baxter International, an American healthcare company, introduced Progressa+ Next Gen ICU bed for addressing critical needs of patients at their homes. This technology makes it easier for nurses to take care of patients, while supporting therapy at home.
In May 2023, Fresenius Kabi, a global healthcare company, initiated an agreement with Premier, Inc., an American healthcare company, that resulted in pricing and term benefits for the Ivenix Infusion System. This system is designed to advance the reliability and simplicity of infusion pumps.
In May 2023, Option Care Health, a healthcare service provider, created an independent platform for home care services in collaboration with Amedisys Inc., a leading provider of home health services. This platform comprises pharmacists, dieticians, therapists, social workers, and others for providing high quality healthcare services at home.
In April 2023, CareFusion, currently owned by Becton Dickinson, an American medical technology company, launched an advanced ultrasound technology to provide clinicians with optimal IV insertions. More than 90% hospitalized patients receive the IV therapy, thus contributing towards the market growth of home infusion therapy.
In January 2022, ICU Medical, a California-based global operations company, finalized the acquisition of Smiths Medical from Smiths Group Plc for creating a leading infusion therapy company with a combined revenue of USD 2.5 billion.
In November 2021, Terumo Corporation, a global medical device company, developed a smartphone device for controlling insulin pump. This device can be utilized as a home infusion therapy by patients for harmonizing the insulin therapy at home.
Report Attribute |
Details |
Market size value in 2022 |
USD 33.5 billion |
Revenue forecast in 2030 |
USD 61.7 billion |
Growth rate |
CAGR of 8.0% from 2023 to 2030 |
Base year for estimation |
2022 |
Historic data |
2018 - 2020 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, competitive landscape, growth factors, and trends |
Segments covered |
Application, Product, Route of Administration |
Regional scope |
North America; Europe; Asia Pacific; Latin America; & MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark, Sweden, Norway, Japan; India; China; Australia; South Korea; Thailand, Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE, Kuwait |
Key companies profiled |
Carex Health Brands, Inc.; Drive Medical Design & Manufacturing; Graham-Field Health Products, Inc.; Invacare; Medline; Sunrise Medical LLC; Karman Healthcare; Quantum Rehab; Numotion; Pride Mobility Products Corp. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional, and segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global home infusion therapy market report on the basis of product, application, route of administration, and region:
Home Infusion Therapy Product Outlook (Revenue, USD Million, 2018 - 2030)
Infusion pumps
Elastomeric
Electromechanical
Gravity
Others
Intravenous Sets
IV cannulas
Needleless connectors
Home Infusion Therapy Application Outlook (Revenue, USD Million, 2018 - 2030)
Anti-Infective
Endocrinology
Diabetes
Others
Hydration Therapy
Athletes
Others
Chemotherapy
Enteral Nutrition
Parenteral Nutrition
Specialty Pharmaceuticals
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Italy
Denmark
Sweden
Norway
Asia Pacific
India
Japan
China
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global home infusion therapy market size was estimated at USD 33.5 billion in 2022 and is expected to reach USD 35.9 billion in 2023.
b. The global home infusion therapy market is expected to grow at a compound annual growth rate of 8.0% from 2023 to 2030 to reach USD 61.7 billion by 2030.
b. North America dominated the home infusion therapy market with a share of 56.5% in 2022. This can be attributed to increasing R&D in the region and the rising adoption of new technology in infusion pumps. The increasing need for long-term therapy for patients with certain conditions is driving the regional market growth.
b. Some key players operating in the home infusion therapy market include B. Braun Melsungen AG; Baxter; Caesarea Medical Electronics; CareFusion Corporation; Fresenius Kabi; ICU Medical, Inc.; JMS Co. Ltd.; Smiths Medical; and Terumo Corporation.
b. Key factors that are driving the home infusion therapy market growth include the increasing geriatric population with decreased mobility profile, rising preference for home care, and rapid technological advancements.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."